Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK105 + anlotinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AK105 + anlotinib + nab-paclitaxel is a combination regimen under investigation for cancer therapy. - **AK105** is a humanized IgG1 monoclonal antibody targeting the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. - **Anlotinib** is a small molecule multi-targeted tyrosine kinase inhibitor that inhibits receptors such as VEGFR, FGFR, PDGFR, and c-Kit involved in tumor angiogenesis and proliferation. - **Nab-paclitaxel** (Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel that acts as an antimicrotubule agent by stabilizing microtubules and inhibiting their depolymerization during cell division[3][4][5]. This combination aims to synergistically inhibit tumor growth through immune modulation (AK105), antiangiogenic effects (anlotinib), and cytotoxic chemotherapy (nab-paclitaxel).
- Other names
- protein-bound paclitaxelnanoparticle albumin–bound paclitaxelalbumin-bound paclitaxel
02
Targets
FGFR (FGFR family)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on AK105 + anlotinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK105 + anlotinib + nab-paclitaxel.